This week, I was making a presentation for Company X and needed to keep abreast of the recent cost per genome figure computed at genome.gov. Well, thanks to a retweet by Michael, it looks like October 1 saw the Second Inflection point we've been waiting for. Time to change the slides and time to think about The Important Things after Commodity Sequencing.
Related:
Let us note that this cost figure still doesn't seem to include neither Pacific BioSciences RSII nor Oxford Nanopore technology cost.
Related:
No comments:
Post a Comment